MA56188A - Traitements de l'oedème de quincke - Google Patents

Traitements de l'oedème de quincke

Info

Publication number
MA56188A
MA56188A MA056188A MA56188A MA56188A MA 56188 A MA56188 A MA 56188A MA 056188 A MA056188 A MA 056188A MA 56188 A MA56188 A MA 56188A MA 56188 A MA56188 A MA 56188A
Authority
MA
Morocco
Prior art keywords
quincke
edema
treatments
Prior art date
Application number
MA056188A
Other languages
English (en)
French (fr)
Inventor
Edward Paul Feener
Andreas Maetzel
Sally Louise Marsh
Michael David Smith
Christopher Martyn Yea
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of MA56188A publication Critical patent/MA56188A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
MA056188A 2019-06-14 2020-06-15 Traitements de l'oedème de quincke MA56188A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861758P 2019-06-14 2019-06-14
GBGB1910125.2A GB201910125D0 (en) 2019-07-15 2019-07-15 Treatments of angioedema

Publications (1)

Publication Number Publication Date
MA56188A true MA56188A (fr) 2022-04-20

Family

ID=67700187

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056188A MA56188A (fr) 2019-06-14 2020-06-15 Traitements de l'oedème de quincke

Country Status (18)

Country Link
US (1) US20220226293A1 (cg-RX-API-DMAC7.html)
EP (1) EP3982961A1 (cg-RX-API-DMAC7.html)
JP (1) JP7640474B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220024221A (cg-RX-API-DMAC7.html)
CN (2) CN113993520A (cg-RX-API-DMAC7.html)
AR (1) AR119159A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020293616A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024447A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142220A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021003243A1 (cg-RX-API-DMAC7.html)
GB (1) GB201910125D0 (cg-RX-API-DMAC7.html)
IL (1) IL288612A (cg-RX-API-DMAC7.html)
MA (1) MA56188A (cg-RX-API-DMAC7.html)
MX (1) MX2021014558A (cg-RX-API-DMAC7.html)
PH (1) PH12021552967A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202113375PA (cg-RX-API-DMAC7.html)
TW (1) TW202112371A (cg-RX-API-DMAC7.html)
WO (1) WO2020249979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
US20250281397A1 (en) 2022-04-27 2025-09-11 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
ES2483802T3 (es) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201609607D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
PL3716952T3 (pl) * 2017-11-29 2022-05-02 Kalvista Pharmaceuticals Limited Postacie dawkowania zawierające inhibitor kalikreiny osoczowej

Also Published As

Publication number Publication date
GB201910125D0 (en) 2019-08-28
JP7640474B2 (ja) 2025-03-05
CA3142220A1 (en) 2020-12-17
SG11202113375PA (en) 2021-12-30
CL2023000699A1 (es) 2023-10-30
AR119159A1 (es) 2021-12-01
JP2022537913A (ja) 2022-08-31
CN113993520A (zh) 2022-01-28
US20220226293A1 (en) 2022-07-21
BR112021024447A2 (pt) 2022-01-18
PH12021552967A1 (en) 2022-07-25
AU2020293616A1 (en) 2022-01-27
MX2021014558A (es) 2022-04-06
CN118078821A (zh) 2024-05-28
TW202112371A (zh) 2021-04-01
EP3982961A1 (en) 2022-04-20
IL288612A (en) 2022-02-01
WO2020249979A1 (en) 2020-12-17
CL2021003243A1 (es) 2022-09-30
KR20220024221A (ko) 2022-03-03

Similar Documents

Publication Publication Date Title
IL281348A (en) Combination therapies
IL277333A (en) Methods for treating eye diseases
IL281344A (en) Combination therapies
IL289485A (en) Neurodegenerative disease therapies utilizing the skin-brain axis
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
PT3873604T (pt) Métodos para tratar a doença de alzheimer com hp-[beta]-ciclodextrina
MA56187A (fr) Traitements de l'angio-oedème héréditaire
MA49295A (fr) Traitements du cancer de l'utérus
EP3853365A4 (en) MODULATORS OF PNPLA3 EXPRESSION
EP3890725A4 (en) COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES
IL272081A (en) Photodynamic therapy method for skin disorders
EP3880235A4 (en) GENE THERAPY OF NEURAL ZEROID LIPOFUSCINOSES
EP3601569A4 (en) PCSK9 EXPRESSION MODULATORS
EP3884053A4 (en) COMPOUNDS AND METHODS FOR REDUCING PRION EXPRESSION
LT3740504T (lt) Cd70 kompleksinė terapija
EP3751048A4 (en) FIBER TREATMENT AGENTS
IL263433A (en) Methods for treating alzheimer's disease
MA53329A (fr) Méthodes de traitement de l'épilepsie
LT4034122T (lt) Hiperfenilalaninemijos gydymo būdai
GB201800274D0 (en) Novel treatments
MA51645A (fr) Modulateurs de l'expression de dnm2
IL281736A (en) Methods of treating myeloproliferative disorders
IL289436A (en) Methods for treating ocular diseases
EP3731928A4 (en) EJACULATION CONTROL
EP3991718A4 (en) HAIR TREATMENT METHOD